Top Tweets for #ETHANstudy

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 9 hours ago

It's #MensBreastCancerAwarenessWeek and @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery for #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/zsYl0craF1 #MaleBreastCancerAwareness @MBCGlobAlliance

DFCI_BreastOnc's tweet photo. It's #MensBreastCancerAwarenessWeek and @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery for #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1

#MaleBreastCancerAwareness @MBCGlobAlliance

0

4

4

0

338

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

4 months ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR https://t.co/BILmsTmELv

1

11

10

0

983

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

5 months ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery for #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery for #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR https://t.co/v56M3HzJTO

0

14

7

1

831

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

7 months ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/zsYl0crIuz PI: Dr. Jose Pablo Leone

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/zsYl0crIuz
PI: Dr. Jose Pablo Leone

0

14

8

2

875

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

8 months ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery for #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery for #MaleBreastCancer.

For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR https://t.co/CRMKX7P67I

0

10

3

2

660

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

12 months ago

The Breast Oncology Center and @TheTBCRC are leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This study is looking to see how well male breast cancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. #MaleBreastCancer research is important because it is rare which means many men don’t know about it and it is often caught late. This research will be key to advancing our understanding of this disease, and to developing the best therapies possible. For more information call 877-DF-TRIAL (877-338-7425) or visit: dana -farber.org/clinical-trials/22-225 #Malebreastcancerawarenessweek #Malebreastcancerawarenes #JosePabloLeone #Breastcancerawarenessweek @MBCGlobAlliance

DFCI_BreastOnc's tweet photo. The Breast Oncology Center and @TheTBCRC are leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This study is looking to see how well male breast cancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer.

#MaleBreastCancer research is important because it is rare which means many men don’t know about it and it is often caught late. This research will be key to advancing our understanding of this disease, and to developing the best therapies possible.

For more information call 877-DF-TRIAL (877-338-7425) or visit: dana -farber.org/clinical-trials/22-225
#Malebreastcancerawarenessweek #Malebreastcancerawarenes #JosePabloLeone #Breastcancerawarenessweek @MBCGlobAlliance

DFCI_BreastOnc's tweet photo. The Breast Oncology Center and @TheTBCRC are leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This study is looking to see how well male breast cancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer.

#MaleBreastCancer research is important because it is rare which means many men don’t know about it and it is often caught late. This research will be key to advancing our understanding of this disease, and to developing the best therapies possible.

For more information call 877-DF-TRIAL (877-338-7425) or visit: dana -farber.org/clinical-trials/22-225
#Malebreastcancerawarenessweek #Malebreastcancerawarenes #JosePabloLeone #Breastcancerawarenessweek @MBCGlobAlliance

DFCI_BreastOnc's tweet photo. The Breast Oncology Center and @TheTBCRC are leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This study is looking to see how well male breast cancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer.

#MaleBreastCancer research is important because it is rare which means many men don’t know about it and it is often caught late. This research will be key to advancing our understanding of this disease, and to developing the best therapies possible.

For more information call 877-DF-TRIAL (877-338-7425) or visit: dana -farber.org/clinical-trials/22-225
#Malebreastcancerawarenessweek #Malebreastcancerawarenes #JosePabloLeone #Breastcancerawarenessweek @MBCGlobAlliance

DFCI_BreastOnc's tweet photo. The Breast Oncology Center and @TheTBCRC are leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This study is looking to see how well male breast cancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer.

#MaleBreastCancer research is important because it is rare which means many men don’t know about it and it is often caught late. This research will be key to advancing our understanding of this disease, and to developing the best therapies possible.

For more information call 877-DF-TRIAL (877-338-7425) or visit: dana -farber.org/clinical-trials/22-225
#Malebreastcancerawarenessweek #Malebreastcancerawarenes #JosePabloLeone #Breastcancerawarenessweek @MBCGlobAlliance

2

10

3

1

2K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 1 year ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR https://t.co/o9wBF8Exnt

0

8

2

1

1K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 1 year ago

The Breast Oncology Center is leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This research study is looking to see how well #MaleBreastCancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. For more information call 877-338-7425 or visit: https://t.co/zsYl0craF1

DFCI_BreastOnc's tweet photo. The Breast Oncology Center is leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This research study is looking to see how well #MaleBreastCancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1

DFCI_BreastOnc's tweet photo. The Breast Oncology Center is leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This research study is looking to see how well #MaleBreastCancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1

DFCI_BreastOnc's tweet photo. The Breast Oncology Center is leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This research study is looking to see how well #MaleBreastCancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1

DFCI_BreastOnc's tweet photo. The Breast Oncology Center is leading the #ETHANstudy, a randomized study for men with stage I-III hormone receptor-positive (HR+)/HER2-negative #BreastCancer. This research study is looking to see how well #MaleBreastCancer responds to pre-surgery treatment with endocrine therapy and which endocrine therapy drug is the most effective treatment for male breast cancer. For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1

0

33

9

3

2K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 1 year ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery. #MaleBreastCancer For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery. #MaleBreastCancer
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR https://t.co/VUSnk5sxOQ

0

4

1

0

362

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 1 year ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer. For more info call 877-338-7425 or visit: https://t.co/wmcrnUX3Np @MBCGAlliance

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more info call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np @MBCGAlliance https://t.co/ChV7H22ieu

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more info call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np @MBCGAlliance https://t.co/ChV7H22ieu

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more info call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np @MBCGAlliance https://t.co/ChV7H22ieu

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more info call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np @MBCGAlliance https://t.co/ChV7H22ieu

0

5

0

0

359

over 1 year ago

We finally have a clinical trial designed specifically for men with breast cancer. @MayoCancerCare and @TheTBCRC have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059.

MayoClinic's tweet photo. We finally have a clinical trial designed specifically for men with breast cancer. @MayoCancerCare and @TheTBCRC have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059. https://t.co/ThpQfc7lsI

0

12

4

0

4K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 1 year ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer For more information call 877-338-7425 or visit: https://t.co/zsYl0craF1 PI: Dr. Jose Pablo Leone

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer
For more information call 877-338-7425 or visit:
https://t.co/zsYl0craF1 PI: Dr. Jose Pablo Leone

0

5

2

1

666

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

almost 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery. For more information call 877-338-7425 or visit: https://t.co/wmcrnUWvXR #MaleBreastCancer

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUWvXR #MaleBreastCancer https://t.co/Rdslm6QBAZ

0

16

3

2

1K

almost 2 years ago

We finally have a clinical trial designed specifically for men with breast cancer. @MayoCancerCare and @TheTBCRC have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059.

MayoClinic's tweet photo. We finally have a clinical trial designed specifically for men with breast cancer. @MayoCancerCare and @TheTBCRC have launched TBCRC059, the #ETHANstudy, a study that may revolutionize pre-operative treatment. For more information, please call 855-776-0015 and reference TBCRC059. https://t.co/6MWg7FFznO

1

2

3

0

4K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUX3Np

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np https://t.co/6RFgJmmAUD

0

7

4

2

989

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer For more information call 877-338-7425 or visit: https://t.co/wmcrnUX3Np

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np https://t.co/4mnUhbj3CU

0

2

1

0

462

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

about 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery for #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUX3Np

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- #BreastCancer prior to surgery for #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np https://t.co/twDBYbfVxd

0

5

3

2

928

Ada Waks @adawaksmd

over 2 years ago

Every voice matters on #RareDiseaseDay. Let's shine a light on male breast cancer, a rare and often overlooked condition. Let's unite, advocate and support much needed research, like the #ETHANstudy, to better understand #MaleBreastCancer.

0

6

3

0

1K

Erica Mayer @elmayermd

over 2 years ago

On #RareDiseaseDay, let's highlight male breast cancer and ongoing efforts like the #ETHANstudy. Let's support research, spread awareness, and strive for better treatments for #MaleBreastCancer.

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUX3Np

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np https://t.co/rl8Xzo6dgh

1

23

8

2

14K

0

34

7

0

4K

Dana-Farber’s Breast Oncology Center

@DFCI_BreastOnc

over 2 years ago

@DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer. For more information call 877-338-7425 or visit: https://t.co/wmcrnUX3Np

DFCI_BreastOnc's tweet photo. @DFCI_BreastOnc and @TheTBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery #MaleBreastCancer.
For more information call 877-338-7425 or visit:
https://t.co/wmcrnUX3Np https://t.co/rl8Xzo6dgh

1

23

8

2

14K

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users